Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.48 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22932091 | 0.80 | CRBN (0.50) | CRBN | |
| SCHEMBL22932179 | 0.78 | CRBN (0.77) | CRBN | |
| SCHEMBL22932093 | 0.75 | CRBN (0.45) | CRBN | |
| SCHEMBL22932062 | 0.73 | CRBN (0.67) | CRBN | |
| SCHEMBL6840740 | 0.71 | SIGMAR1 (0.66) | OPRM1OPRD1OPRK1OPRL1CYP2D6 | |
| SCHEMBL10819303 | 0.70 | CYP2D6 (0.60) | OPRM1OPRD1OPRK1OPRL1CYP2D6 | |
| SCHEMBL28219815 | 0.70 | CYP2D6 (0.60) | OPRM1OPRD1OPRK1OPRL1CYP2D6 | |
| SCHEMBL21496463 | 0.70 | CRBN (0.62) | CRBNCYP2D6 | |
| SCHEMBL9479601 | 0.70 | CYP2D6 (0.54) | OPRM1OPRD1OPRK1OPRL1CYP2D6 | |
| SCHEMBL21496439 | 0.69 | CRBN (0.78) | CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584748-B2 | Spirocyclic compounds | C4 THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210032245-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2021-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210032245-A1 | SPIROCYCLIC COMPOUNDS | CRBN, RBX1, XIAP | CRBN 1/4885OPRM1 4739/4885OPRD1 4119/4885 |
| US-11584748-B2 | Spirocyclic compounds | CRBN, RBX1, XIAP | CRBN 1/4885OPRM1 4739/4885OPRD1 4119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.